Hanny Al-Samkari, MD, Massachusetts General Hospital, Boston, MA, discusses the long-term risks associated with persistent isolated mild thrombocytopenia (PIMT). Dr Al-Samkari explains that although PIMT diagnoses are common, there are currently no guidelines for addressing this condition. Dr Al-Samkari describes a recent study evaluating patients diagnosed with PIMT, showing that this patient group is at an elevated long-term risk of immune thrombocytopenia (ITP), myeloid or lymphoid hematologic neoplasms, severe bleeding episodes, and mortality compared to age- and sex-matched controls. Given these long-term risks, Dr Al-Samkari concludes by emphasizing the importance of developing clinical guidelines for patients upon a diagnosis of PIMT. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
